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II. Introduction
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that is the
causative agent of sexually transmitted infections (STI) and the ocular disease known
as trachoma (CDC.gov). Trachoma is the leading cause of preventable blindness
worldwide and most heavily affects developing nations (WHO.org). C. trachomatis
causes over 1.5 million STIs each year in the U.S. alone and is of particular concern to
women as 70–80% of genital tract infections are asymptomatic and 15–40% ascend to
the upper genital tract, which can lead to serious diseases including pelvic inflammatory
disease, infertility, and ectopic pregnancy2. C. trachomatis STIs have also been shown
to facilitate the transmission of HIV and are associated with increased risk of cervical
cancer in HPV-infected women2. Although chlamydial infections are currently treatable
with antibiotics, drug resistance has been observed in vitro, treatment failure occurs
clinically (although the underlying cause of failure remains unclear), and chlamydial
reservoirs in the intestine are not susceptible to drug concentrations that are effective in
clearing genital tract infections. In addition, a vaccine has not been developed 3.
Collectively, the large numbers of infections and sub-optimal methods available for
treatment and prevention suggest that alternative approaches are needed for
combatting C. trachomatis.

Figure 1. The biphasic developmental cycle of Chlamydia. Chlamydia
differentiates between the infectious elementary body (EB) and the replicative reticulate
body (RB). Chlamydia begins the infection in the EB form before differentiating into the
RB to replicate within an inclusion; after multiple replications, the RBs will
asynchronously differentiate back into EBs before exiting the cell. Under stress
conditions, Chlamydia will enter a form of low activity termed persistence. Times are
given in terms of hours post infection (hpi).
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C. trachomatis has been shown to undergo a unique biphasic developmental
cycle in which it differentiates between two functionally distinct forms5 (Fig 1). At the
initial time of infection, C. trachomatis exists in its infectious form known as the
elementary body, or EB. The EB is an electron dense structure that initiates cellularuptake and creates a vacuole out of the host cell’s membrane termed an inclusion.
Proteins required for central metabolism and glucose catabolism were more prevalent in
the EB form, suggesting that a basal metabolism is required outside of the cell to
facilitate EB maintenance and cellular invasion4. Within the inclusion, C. trachomatis will
then differentiate into the reticulate body (RB) form which is characterized as a larger
and less dense structure that replicates within the inclusion. In the RB form, C.
trachomatis synthesized more proteins associated with protein synthesis, ATP
transport, and nutrient transport suggesting that the RB form is more focused on
utilizing available nutrients, increasing cellular mass, and obtaining resources to divide
and eventually differentiate back into the EB form4.
The different forms and “life-styles” of the EB and RB necessitate differences in
gene activation and protein content. Multiple transcriptomic and proteomic studies have
documented these differences. Consequently, Chlamydia need a mechanism to aid in
proteome turn-over during differentiation. Additionally, and conserved amongst other
organisms, Chlamydia also require a system for degrading proteins that are mis-folded,
damaged, or no-longer needed. While mechanisms carrying out both limited and global
protein degradation would appear to be essential for chlamydial growth and
development, making them excellent therapeutic targets, it remains unknown how
protein degradation occurs in these highly significant pathogens.

Figure 2 The Clp system. The Clp proteins will form homo-oligomers of heptamers
(ClpP1/P2) and hexamers (ClpC/X) which will then oligomerize together (A). While the
proteases can function without ATP, the adaptors are ATP-dependent. These protease
heptamers are normally seen with a narrow opening, but the activating compounds can
aid in opening up the barrel (B).
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The Clp protease system is a conserved protein complex that is responsible for
regulating proteomic turnover in bacteria and some eukaryotes (Fig 2). This system is
comprised of two main parts: the proteasome complex comprised of ClpP (the “trashcompactor”) and various adaptor proteins (the “trash-collectors”) that target proteins to
and help to feed proteins into the proteasome. All chlamydial genomes appear to have
components of the Clp system based on annotation and we hypothesize that the Clp
system is essential for chlamydial development and therefore infection. The protease
complex is comprised of the ClpP protein(s) (ClpP1 and ClpP2 in Chlamydia) while the
adaptors for Chlamydia are ClpC and ClpX. These proteins are non-functional in their
single form, meaning one ClpP protein has no protease activity. However, when it
oligomerizes with other ClpPs they form a barrel unit comprised of seven proteins. This
heptameric barrel will then oligomerize on top of a second barrel to create the active
dodecatetramer form. In this double-barrel form, the ClpP proteasome can only degrade
small peptides and a limited number of unfolded protein substrates as the opening at
the top of the double barrel is relatively narrow. As a method of regulation, the adaptor
protein will open the barrel and selectively target proteins to the proteosome. ClpC and
ClpX will each form a hexameric barrel, which will then bind to the top and bottom of the
ClpP double barrel and unfold proteins to feed them into the barrel. In Bacillus subtilis, it
has been shown that arginine phosphorylation via McsA/McsB will target specific
proteins for degradation, similar to ubiquitination in eukaryotes, which the adaptor
proteins will respond to and only open the proteasome for those targeted proteins 10.
As the Chlamydia genome is small (1.039 megabases) due to reductive evolution
during its life-span as an obligate, intracellular bacterium, it is expected that it only
encodes for those proteins absolutely necessary for survival6. For this reason, it is
interesting to note that Chlamydia encode two paralogs of the ClpP protein, ClpP1 and
ClpP2. This protein is a well characterized protease in other organisms; however, in
most other organisms, such as Escherichia coli, there is only one ClpP. In the
organisms that encode two ClpPs they have been shown to interact with each other,
such as in Mycobacteria7. As the Clp proteins have been shown to interact with each
other in other organisms it is possible they might in Chlamydia as well; however, it is
also possible they preform distinct functions as shown in Pseudomonas9.
The increased prevalence of antimicrobial resistant strains across clinicallyrelevant bacterial species has led to a frantic search for new antimicrobials and
antimicrobial targets. The essentiality of the Clp system based on genetic studies in a
number of bacteria makes it an attractive target for drug development. ClpP activating
compounds have been identified that will open up the ClpP proteasome to cause
unregulated degradation of proteins in other organisms7. These activating compounds
are the acyldepsipeptides (ADEP) and activators of cylindrical proteases (ACP) and
they have distinct mechanisms of action. In Bacillus subtilis the ADEP compounds were
crystalized in their bound form to the ClpP proteins and it was discovered they bind to
the H pocket of the formed oligomers, hypothetically mimicking the binding of the
adaptor proteins, and open the double barrel11. ACPs, in comparison, have been seen
to bind at two different regions, the H pocket and the C pocket, and are hypothesized to
3

steady the formation of the double barrel that is expected for the ClpP proteins 11. Both
approaches lead to the same desired result – lethality for the bacterium.
For this study, we hypothesized that the Clp system plays an essential role in the
proteomic turnover needed for differentiation between the EB and RB, and therefore is
required for the developmental cycle. As a first test of our hypothesis we sought to
determine if the ClpPs were functional using various in vitro approaches and whether
ClpP functionality is required for chlamydial growth. The latter point was tested using a
cell-culture infection model with various ACPs. We determined that 1) ClpP2, but not
ClpP1, appears to be active in vitro under the conditions tested, 2) that ClpP2 is
expressed during development, and 3) that ClpP2 activating compounds severely inhibit
chlamydial growth in tissue culture.

4

III. Results
We initially sought to determine if the clp genes were expressed in C. trachomatis. This
work was done by Scot Ouette's group (data not shown) and corroborated by our lab by
looking at protein production through Western blot analysis. To detect protein
expression, we took advantage of a prior study on Pseudomonas aeruginosa, in which
antibodies were synthesized against PA1801 (P. aeruginosa ClpP1) and PA3326 (P.
aeruginosa ClpP2). The antibody against P. aeruginosa ClpP1 showed amino acid
sequence similarity to C. trachomatis ClpP2 and it was confirmed through western blot
analysis that the antibody would bind ClpP2 (Fig 3A). Using this data, it was found that
ClpP2 is expressed in C. trachomatis at 24, 30, and 40 hours post infection (Fig 3B)
when RBs would be converting to EBs.
.

Figure 3 Western blot analysis of ClpP2 expression in C. trachomatis. Purified
proteins were run on 12% SDS-PAGE gels and then transferred to nitrocellulose for antiClpP2 tag western blot (A and B). Coomassie brilliant blue (C) and anti-MOMP western blot
(D) controls were also run. Expected molecular weights for the recombinant proteins: ClpP1
22 kDa and ClpP2 23 kDa,

Escherichia coli BL21(de3) was used to produce the respective ClpP proteins using the
lac operator and T7-promoter regulated pLATE31 vector (Fig 4). Each Clp protein gene
was cloned into the multiple cloning site of the pLATE31 vector using ligation
independent cloning.
5

Figure 4 Clp protein producing plasmids. The clpP1 (ctl0690), clpP2 (ctl0075),
clpP1SDM, and clpPec genes were cloned into pLATE31 at the multiple cloning site (starred
region) to produce C-terminal His-tagged recombinant proteins under control of the lac
operator and T7 RNA polymerase promoter

The proteins were then affinity purified using cobalt-based immobilized metal
affinity chromatography. The ClpP1 product appeared to have two proteins at different
sizes (Fig 5) as seen by the double band. It was determined through mass spectrometry
that the smaller band protein sequence began at a second methionine located within the
ctl0690 gene, while the larger band had the predicted native start site methionine (Fig
5). To address this potential problem as the N-terminal sequence is crucial for
oligomerization, a mutant of the ClpP1 protein was created where the second and third
internal methionines were replaced with an isoleucine and leucine, respectively. This
mutant was called ClpP1SDM. ClpP2 did not express this double band and was
therefore utilized in its native form. As a positive control, E. coli ClpP was expressed
and purified for assays (ClpPec). Purifications of ClpP1(SDM) and ClpP2 were
completed multiple times.
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Figure 5 Purification of recombinant ClpP1, ClpP1SDM, ClpP2, and ClpPec.
Purified proteins were run on 12% SDS-PAGE gels and then either stained with Coomassie
Brilliant Blue (A) or transferred to nitrocellulose for anti-His tag western blot (B). Expected
molecular weights for the recombinant proteins: ClpP1 22 kDa, ClpP1SDM 22 kDa, ClpP2 23
kDa, ClpPec 24 kDa.

Activity was assessed for ClpP1, ClpP2, ClpP1SDM, and ClpPec using an
oligomerization assay, digestion of a small fluorescent peptide, and digestion of casein
in the presence or absence of potential activating compounds. Oligomerization assays
were performed using native-PAGE gels and demonstrated that ClpPec formed the
strongest dodecatetramer, while ClpP2 and ClpP1 formed primarily the heptamer with
modest dodecatetramer, while ClpP1SDM appears to only form the heptamer (Fig 6).
These results suggest an in vitro functionality ranking of ClpPec being more active than
ClpP1 and ClpP2, which are about equal, and those are more active then ClpP1SDM.
To more directly address protease activity further experimentation was performed.
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Figure 6 The ClpP proteins form oligomers. Purified proteins were run on a NativePAGE gels and then stained with Coomassie Brilliant Blue. Expected molecular weights for
the heptamer and dodecatetramer oligomers: ClpP1 154/308 kDa, ClpP1SDM 154/308 kDa,
ClpP2 161/322 kDa, ClpPec 168/336 kDa.

Activity was initially assayed using a fluorescent substrate, Suc-Leu-Tyr-ACM,
which when cleaved releases AMC to fluoresce (Fig 7A). The fluorescence readout is
directly proportional to the level of ClpP activity and readings were taken over six hours.
It was seen that while ClpPec was very active throughout the assay, ClpP1 and
ClpP1SDM were both found to be inactive, and ClpP2 had detectable, but modest
activity (Fig 7B). There was a two-fold increase in fluorescence between ClpP1 (at
baseline) and ClpP2 (Fig 7C).
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Figure 7 ClpP2 is active in vitro while ClpP1 is not. The ClpPs (1 µM) were
incubated with the fluorometric peptide Suc-Luc-Tyr-AMC at 37°C for 6 hours. The peptide
fluoresces when cleaved at the site indicated (A). Relative fluorescence units were recorded
at five-minute intervals and the average of all time course traces are shown in (B). The
average values are reported with standard error in (C, n = 3).

An in vitro assay supported these findings, in which β-Casein was used to test
the protease activity of the ClpP analogs with and without the activating compounds. βCasein is a much larger protein than Suc-Leu-Tyr-AMC, and the ClpP analogs should
be unable to degrade it without an adaptor protein to unfold the substrate or an
activating compound to increase the barrel opening. It was found that ClpPec, ClpP1,
and ClpP2 were all unable to degrade β-casein. However, upon the addition of 10 µM of
ADEP1, and 500 µM of the ACP1, ACP1a, and ACP1b β-casein was mostly degraded
by ClpPec and ClpP2 after 3 hours (Fig 8).

Figure 8 ACP and ADEP activate ClpP2, but not ClpP1. Reactions were run at
37°C for 3 hours with 1 µg of casein. ADEP1 was used at 10 µM and other compounds
were used at 500 µM. Representative gels are shown.
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Figure 9 ClpP activating compounds inhibit C. trachomatis growth. In vitro results
were corroborated with an in vivo assay. HeLa cells were infected with C. trachomatis at a
MOI of 0.2 and activators were used at a concentration of 50 µg/mL. Wells were imaged at
24 and 48 hours post infection (24 shown). No bacteria were present in the presence of
inhibitors at 48 hours post infection as well.

After demonstrating that: 1) ClpP2 is expressed and the protein could be
detected during growth, 2) ClpP2 oligomerizes, 3) ClpP2 can cleave a peptide
substrate, and that 4) ClpP2 activity is stimulated towards casein using ACP and ADEP,
we sought to test whether ClpP2 activation would disrupt chlamydial growth.
Compounds were previously identified as antibacterial like compounds in other
organisms specifically targeting the bacterial Clp system. These activating compounds,
known as acydepsipeptides (ADEP compounds) and activators of cylindrical proteases
(ACP compounds), have been seen in E. coli to enhance ClpP activity. ADEP1, ACP1,
ACP1a, and ACP1b were seen in vivo to enhance C. trachomatis Clp system activity
(ADEP1 not pictured) (Fig 9). C. trachomatis strain DFCT28 has been modified to
express GFP. Infected cells were treated with 50 µg/mL of each specified activating
compound in duplicate and the chlamydial growth was inhibited in all wells. The
untreated infected cells and DMSO treated infected cells showed no change in growth
(Fig 9).
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IV. Discussion
In this study, we sought to biochemically characterize the C. trachomatis proteins
ClpP1 and ClpP2 with the goal of validating the Clp system of Chlamydia as a
therapeutic target. Our data is indicative of the Clp system playing an essential role in
the development of Chlamydia, as it is expressed at specific time points in the
development cycle and unregulated activity caused chlamydial cell death.
This study began by testing Clp protein expression in C. trachomatis to
determine at what point in the developmental cycle the Clp proteins may regulate
proteomic turnover. To do so, an antibody was identified as specific for Pseudomonas
aeruginosa ClpP1 and C. trachomatis ClpP2. When a western blot was run using
infected L2 cells at varying points in the developmental cycle, ClpP2 was detected at
24, 30, and 40 hours post infection. This correlates to the differentiation from RB back to
EB at about 24 hours post infection up until the release of EBs from the host at about 40
hours post infection. This correlates well with our hypothesis that the Clp system
regulates proteomic turnover from one developmental form to the next as it is initially
expressed at the specific time point in the developmental cycle known for that exact
transition. However, ClpP2 expression is lacking at the initial transition from elementary
to reticulate body, though this is not entirely surprising as we are open to the idea that
the elementary body form comes prepackaged with all the proteins and nutrients
needed to make this single transition. It is also possible that ClpP1 is critical for early
steps, but it may require an adaptor protein for functionality (such as ClpX/C) that has
yet to be identified.
As discussed earlier, ClpP proteins are not active until they are in their
dodecatetramer double barrel. From the oligomerization assays it became clear that the
purified ClpP proteins from C. trachomatis did not readily oligomerize, while those from
E. coli did. The E. coli band was significantly stronger and this could be the result of
expressing the protein, ClpPec, in its original organism, which would easily lend to
proper folding as it is in its ideal environment. Chlamydial proteins, on the other hand,
were not in their ideal environment for expression, as they were expressed in E. coli,
rather than C. trachomatis. Soluble protein was purified and some oligomerized forms of
the protein could be seen, but they were stronger at the expected size for heptamers
rather than the dodecatetramers. This does not mean that the proteins are inactive,
however, as the fluorescence and Casein assays are indicative of ClpP2 activity, simply
that with the current expression system the proteins may be less active than they would
be in their native form. For this reason, it is important to note our in vivo studies that
show a low amount of activating compound is still enough to cause Chlamydia cell
death. In their native environment, ClpP activity may be stronger than our in vitro
studies have shown with the current models.
While we initially saw ClpP2 can readily degrade a small fluorescent peptide,
ClpP1 was unable to do so. We hypothesized this may be due to the two ClpP1 proteins
that were identified on an SDS-PAGE gel and verified by mass spectrometry. This led
us to create a mutant of ClpP1 through site directed mutagenesis to replace the internal
12

methionines with an isoleucine and leucine, creating ClpP1SDM. When this mutant was
tested in the same fluorescence assay, it did not show the same level of activity as
ClpP2. One purification did show a high level of activity, but later multiple purifications
did not, causing us to conclude the initial purification may have been contaminated with
ClpPec. From this it appears that ClpP1 may need an additional protein/peptide for
proper function, or the isoleucine and leucine rendered it inactive and a different mutant
needs to be created.
This finding was further supported by the β-Casein assay that found ClpP2, with
the assistance of activating compounds, could degrade β-Casein while ClpP1 could not.
This lack of activity is indicative of there either not being a fully formed ClpP1 double
barrel, which is supported by the oligomerization assay, a mix of proper ClpP1 proteins
and those lacking 4 amino acids, which might lead to inactivity, or ClpP1 is simply
inactive in Chlamydia. It is unlikely that ClpP1 has no activity considering the chlamydial
genome is so small, as previously discussed, but still possible.
The in vivo assay is incredibly important to this study as it exemplifies the
importance of the Clp system in Chlamydia's developmental cycle, based on the
clearance of the infection upon the addition of the activating compounds. Also, as seen
in the non-GFP images, the cells that had the infection cleared look healthy and normal,
supporting the idea that while the activating compounds are non-specific among
bacterial species, they might not target the hosts' Clp system or inhibit cells under the
conditions tested.
From this study, we were unable to determine any interaction between the ClpP1
and ClpP2 proteins nor determine if there is any specificity between each ClpP analog
and the ClpC/X adaptor proteins. This is a source for further experimentation and study
as well as the determination of more specific activating compounds. While the in vivo
assay supported that the hosts Clp system was unaffected by the activating compounds
there are still beneficial microbiota in multicellular organisms that an ideal treatment
would not target. Other activating compounds have already been identified, but they did
not exhibit species specificity and had a lessened effect on the Chlamydia in vivo.
Based upon findings from this study, the Clp system appears functional in
Chlamydia and our in vitro and in vivo results support the Clp system as a novel target
for drug development.
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V. Methods
Cloning of the ClpP genes
Table 1: Primers used to isolate genes. The primers were designed using Clone
Manager.
Primers Used
Reverse Primer

Gene

Forward Primer

ctl0075

AGAAGGAGATATAACTATGACGTT
GGTACCATACGTTGTTGAAG
AGAAGGAGATATAACTATGCCTGA
AGGGGAAATGATGCATAAG
ATAGAAAGTTGTTGGATTCTCGTC
G

ctl0690
ctl0690
mutant
eck0431

GTGGTGGTGATGGTGATGGCCAG
ACGCAATACTCTTATCTTTTGTC
GTGGTGGTGATGGTGATGGCCCAA
GTCGTTAAAAGAGAAGAGAATCCC
CTATGACATCTTGCAACTTATGAAT
CAGTTCCCCTTCAGGCATAGTTATA
TC
AGAAGGAGATATAACTATGTCATAC GTGGTGGTGATGGTGATGGCCATT
AGCGGCGAACGAG
ACGATGGGTCAGAATCGAATCG

The clpP1 (ctl0690), clpP2 (ctl0075), clpP1SDM and clpPec genes were
amplified through PCR using the primers designated in the above table and inserted
into the vector pLATE31using the LIC procedure as described by the Fisher Scientific
(Kit #K1261). The primers were designed using Clone Manager and the completed
vectors were then transformed into Escherichia coli NEB10 competent cells through
chemical transformation and transformants were selected on LB agar plates
supplemented with 100 µg/ml ampicillin. Clones were assessed for the gene inserts
using PCR and the plasmid was then extracted using the GeneJet Plasmid purification
kit (Fisher Scientific #K0502). The plasmid was then sequence verified and transformed
into Escherichia coli BL21 (de3) through electroporation for protein expression.
Protein Expression and Purification
The ClpP constructs were induced at 0.5mM IPTG at 18°C for 20 hours in E. coli
BL21 (de3). Both proteins are fused to a His tag and were purified using immobilized
metal affinity chromatography with HisPur Cobalt Agarose resin (Fisher Scientific). The
culture was grown in 500mL of lysogeny broth with ampicillin to an OD600nm reading of
0.6. After induction the sample was centrifuged at 13,000g for 20 minutes, washed in
PBS, and frozen overnight. The pellet, after thawing, was then resuspended in a 1:101:12.5 solution of Buffer A. The cells were lysed through sonication in five, ten second
bursts. The sample was again centrifuged at 13,000g for 20 minutes. The soluble
portion was then filter sterilized into a bed of 200µL of resin. The protein was bound to
the resin for 1 hour, after which, the resin was spun down at 700g for 5 minutes at 4°C
and the supernatant was then discarded. The resin was washed with 400µL of Buffer A,
centrifuged at 700g for 1 minute, and the A280 value was read until it leveled out. Then
200µL of Buffer B was added to the resin, mixed, and centrifuged at 700g for 5 minutes.
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This was repeated three more times. Each step was run on an SDS-PAGE gel to
confirm protein purification and elution, and then the protein yield was concentrated by
pooling all of the elution samples in an Amicon unit, adding 10mL of Buffer C, and
centrifuging it at 4,000g for 90 minutes. This was repeated two more times. The final
protein preparation was stored at -80°C and protein concentrations were determined by
a Bradford Assay.
Buffer compositions:
Buffer A: 25mM Tris (pH 7.5), 150mM NaCl, 10mM Imidazole, 10% glycerol
Buffer B: 25mM Tris (pH 7.5), 150mM NaCl, 300mM Imidazole, 10% glycerol
Buffer C: 25mM Tris (pH 7.5), 150mM NaCl, 10% glycerol

Western blots: Pseudomonas aeruginosa ClpP1 and ClpP2 antibody comparison
and His-tag detection
The P. aeruginosa antibodies were rabbit poly-clonal antibodies and were used
at the following concentrations: α-ClpP1 antibodies were used at a concentration of
1:10,000, while α-ClpP2 antibodies were used at a concentration of 1:5,000. A test was
run of α-ClpP2 antibodies with 1:2,500 with no change in results. α-His antibodies were
mouse monoclonal and were used at a 1:2,500 concentration.
The western blot to test for antibody compatibility was run at 300mA for an hour
for the transfer of 200ng of each specified protein to nitrocellulose. The blot was blocked
using milk protein (casein) for 1 hour at room temperature, the primary antibody was
applied overnight at 4°C, and the secondary antibody was applied for 1 hour at room
temperature.
The only differences that were applied to the time point western blot were that
the transfer was run at 325mA and only 50ng of ClpP2 protein were used. For each time
point, 25µl of C. trachomatis protein sample were used, 12µl of L2 lysate and 5µl of
HeLa lysate were used.
Oligomerization Reactions
Table 2: Expected Protein Sizes of Oligomers. Protein sizes were calculated using
the bioinformatics.org website and then multiplied by 7 or 14.

Protein
ClpP1
ClpP1SDM
ClpP2
ClpPec

Protein Sizes
Weight (with tag)
Oligomer
22kDa
Heptamer
Tetradecamer
22kDa
Heptamer
Tetradecamer
23kDa
Heptamer
Tetradecamer
24kDa
Heptamer
Tetradecamer

Weight
154kDa
308kDa
154kDa
308kDa
161kDa
322kDa
168kDa
336kDa
15

The oligomerization reacts were set up to run at room temperature for 40 minutes
in Buffer D supplemented with either nothing, 1mM of ATP, or 1mM AMP-PNP. Each
reaction had 2µg of protein. The reactions were then mixed with native-PAGE buffer
and run on a 4-20% native-PAGE gel at 200 volts for 90 minutes. The final gel was
stained with Coomassie brilliant blue.
The second and third biological replicates, run with another batch of purified
protein were incubated only in Buffer D but for 1 hour at 37°C with 5µg of protein. This
replicate also tested the efficacy of the ClpP activators: ACP1 and ACP1a.
Buffer compositions:
Buffer D: 25mM Tris-HCl (pH 7.5), 5mM KCl, 5mM MgCl2, 10% glycerol, 1mM DTT

Fluorescent Peptidase Assay
These experiments were conducted by incubating 1µM of ClpP protein with
500µM of peptide Suc-Luc-Tyr-AMC in Buffer E. Papain was used as a positive control
at 0.1µM. Each experiment was a 50µL reaction that was run in duplicate on a 96 well
plate and measured for fluorescence with an excitation at 340/360nm and a reading at
440/460nm. The experiment was conducted over 6 hours at 37°C with readings taken
every 5 minutes.
Buffer compositions:
Buffer E: 50mM Tris-HCl (pH8), 200mM KCl, 1mM DTT

Casein Degradation Assay

Reactions were set up with 1µM of ClpP, 1µg of casein per time point, Buffer E
and a specified amount of activator in an Eppendorf tube. The reaction was carried out
at 37°C for 3 hours. The reaction was then immediately mixed with 2x Laemmli buffer
and boiled at 90-100°C for 10 minutes. Each time point was then run on a 12% SDSPAGE gel for visualization. Activators were prepared by Dr. Conda-Sheridan at the
University of Nebraska Medical Center
Buffer compositions:
Buffer E was modified to include casein at a concentration of 1µg/µL
In vivo antimicrobial assay
Mouse L2 cells were infected with GFP expressing C. trachomatis at a multiplicity
of infection of 0.2. Eight hours after being infected, wells were treated in duplicate with
50µg/mL of the activating compound. The inclusions were then imaged 24 hours post
infection using fluorescence microscopy.
16
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